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The spiral arteries undergo physiologic changes during pregnancy, and the failure of this process may lead to a spectrum of preg-
nancydisorders,includingpre-eclampsia.Ourrecentdataindicatethatdecidualendothelialcells(DECs),coveringtheinnersideof
the spiral arteries, acquire the ability to synthesize C1q, which acts as a link between endovascular trophoblast and DECs favouring
theprocessofvascularremodelling.Inthisstudy,wehaveshownthatseraobtainedfrompre-eclampticpatientsstronglyinhibitthe
interaction between extravillous trophoblast (EVT) and DECs, preventing endovascular invasion of trophoblast cells. We further
demonstrated that mannose-binding lectin (MBL), one of the factor increased in pre-eclamptic patient sera, strongly inhibits the
interaction of EVT with C1q interfering with the process of EVT adhesion to and migration through DECs. These data suggest
that the increased level of MBL in pre-eclampsia may contribute to the failure of the endovascular invasion of trophoblast cells.
1.Introduction
The decidua is a newly formed tissue on the maternal side of
human placenta and is characterized by active angiogenesis
and structural modiﬁcations of the spiral arteries in the ear-
ly phase of pregnancy. These changes, that include gradual
loss of the musculoelastic structure of the arterial wall and
replacement by amorphous ﬁbrinoid material, are essen-
tial to create vessels of low resistance unresponsive to vaso-
constrictive agents [1, 2] allowing continuous blood ﬂow in
the intervillous space.
An additional feature of the physiologic changes of spiral
arteries is the endovascular invasion of extravillous tropho-
blast (EVT) that adheres to and replaces endothelial cells
(ECs) giving rise to mosaic vessels in which trophoblast and
ECs coexist [3]. Recently, we have provided data indicating
that decidual endothelial cells (DECs) lining the spiral arter-
ies acquire the ability to synthesize C1q. This protein binds
avidly to the cell surface and acts as a physical link between
endovascular trophoblast and DECs favouring the process of
vascular remodelling [4]. C1q is a recognition molecules of
the complement (C) system, one of the major components
of humoral innate immunity, acting as a ﬁrst line of defence
against microbes. The C system can be activated via three
pathways, namely, the classical, the alternative, and the lec-
tin pathway, which are triggered by the three recognition
molecules, C1q, C3, and mannose-binding lectin (MBL),
respectively [5]. The system is also involved in the elimi-
nation of dead or modiﬁed self cells [6], but new roles in
inﬂammatory, immunological processes, and tissue remod-
elling are emerging.
Failure of spiral artery to undergo transformation may
lead to a spectrum of pregnancy disorders, including pre-
eclampsia [7], foetal growth restriction, and miscarriage
[8, 9]. Pre-eclampsia is a complication of pregnancy charac-
terized byhypertensionandproteinuria anddevelops in nor-
motensive pregnant women after midgestation. Inﬂamma-
tion and innate immunity seem to play an important role
in the aetiology of pre-eclampsia [10]. Several recent studies
suggest an association between increased complement dys-
regulation and pre-eclampsia [11]. The role of the lectin
pathwayintheonsetofthissyndromeisacontroversialissue.2 Clinical and Developmental Immunology
The activity of MBL-MBL associated serin proteases
(MASP)2 complexes is not increased in pre-eclamptic (PE)
women [12]. A higher concentration of MBL has been dem-
onstrated in the plasma of patients, compared to nor-
mal pregnant women [13] although the functions of this
molecule in pregnancy remains to be clariﬁed, despite the
increased serum MBL concentration during pregnancy [14].
The association of a genetically related MBL polymorﬁsm
with MBL decreased functional activity has been reported to
be protective against pre-eclampsia [15]. The level of MBL in
the vaginal cavity changes during the menstrual cycle being
produced locally by vaginal cells [16]. MBL seems to play an
important role in embryo implantation since the analysis of
uterine ﬂushings, obtained at the time of oocyte retrieval for
theinvitrofertilisation,revealedanincreasedlevelofMBLin
patients with unexplained infertility compared with patients
involved in IVF/ICSI for male or tubal infertility [17].
The aim of the present study was to evaluate the eﬀect
of sera obtained from pre-eclamptic patients on the process
of vascular remodelling using in vitro models of trophoblast
adhesion to and migration through DECs. We further
investigate the ability of MBL to interfere with the process
of trophoblast-endothelial cell interaction in order to deﬁne
one possible mechanism responsible for the endovascular
invasion failure in this severe multifactorial disease.
2.MaterialandMethods
2.1.StudyGroups. Inthisstudy11pre-eclampticand11nor-
mal pregnant women matched for gestation and parity were
enrolled. The diagnosis of pre-eclampsia was established ac-
cording to the standard criteria [18]. An informed consent
was obtained from all women participating to the study. The
study was approved by the Bioethical Committee of IRCCS,
Burlo Garofolo, Trieste, Italy.
2.2. Collection and Processing of Sera and Measurement of
MBL. Serum samples were obtained antepartum at the time
of clinical diagnosis of the syndrome. The level of MBL in
the sera was measured using the MBL oligomerELISA kit
(Bioporto/Antibodyshop, Gentofte, Denmark).
2.3. Cell Isolation and Culture. EVT was puriﬁed from
placental specimens after removal of decidual tissue and
fetal membrane as previously described [3]. Brieﬂy, placental
tissue was incubated with HBSS containing 0.25% trypsin
and 0.2mg/mL DNase (Roche, Milan, Italy) for 20min
at 37◦C. After fractionation through Percoll gradient, the
leukocytes were totally removed by immunomagnetic beads
coated with mAb to CD45 (Dynal, Invitrogen, Milan, Italy).
EVT collected by negative selection were seeded in 25-cm2
ﬂask coated with 5µg/cm2 ﬁbronectin (FN, Roche), cultured
overnight in RPMI 1640 (Gibco, Invitrogen), supplemented
with 10% FCS, and ﬁnally detached by trypsin-EDTA treat-
ment. The cells obtained under these conditions contained
95% cytokeratin 7-positive EVT and a few vimentin-positive
stromal cells. The presence of contaminating leucocytes and
ECswasexcludedbyRT-PCRassayforCD45andFACSanal-
ysis with anti-vWF and anti-CD31 antibodies, respectively.
DECs were isolated from decidual biopsy specimens as
previously described with some modiﬁcations [3]. Brieﬂy,
the tissue was ﬁnely minced, digested ﬁrst with 0.25% tryp-
sin (Sigma-Aldrich, Milan, Italy) and 50µg/mL DNase I
(Roche) overnight at 4◦C, and then with collagenase type 1
(3mg/mL) (Worthington Biochemical Corporation, DBA,
Milano, Italy) for 30 minutes at 37◦C. The cells collect-
ed at the interface of Ficoll-Paque gradient (G&E Healthcare,
Milan, Italy), after the centrifugation of the cell suspen-
sion at 690×g for 30 minutes, were positively selected
with Dynabeads M-450 (Dynal, Invitrogen) coated with
Ulex europaeus 1 lectin (Sigma-Aldrich). Cytoﬂuorimetric
analysis showed that more than 95% of the cells stained
for vWF (Dako-Cytomation, Milan, Italy). The cells were
seeded in 12.5-cm2 ﬂaskprecoatedwith 5µg/cm2 ﬁbronectin
(Roche) and maintained in endothelial serum-free basal
medium (GIBCO, Invitrogen) supplemented with 20ng/mL
bFGF (basic ﬁbroblast growth factor) and 10ng/mL EGF
(epidermal growth factor) (GIBCO, Invitrogen).
2.4. In Vitro Immunoﬂuorescence Analysis. EVT or DECs
were plated on 8-chamber culture slides (BD Biosciences
Discovery Labware, Milan, Italy) coated with FN (10µg/mL)
at 37◦C and left to adhere for 2h. After ﬁxation and perme-
abilization with FIX&PERM kit solutions (Invitrogen), EVT
was stained with mAb OV-TL 12/30 anticytokeratin 7 (CK7,
Dako-Cytomation, Milan, Italy), and DECs were stained
with mAb BV9 antihuman VE-cadherin obtained through
the courtesy of E. Dejana (Mario Negri Institute, Milan,
Italy).Thebindingoftheseantibodieswasrevealedwithgoat
antimouse FITC-conjugated secondary antibodies (Dako-
Cytomation). Images were acquired using a Leica DM3000
microscope (Leica, Wetzlar, Germany) and the pictures were
collected using a Leica DFC320 digital camera (Leica).
2.5.EVTAdhesionAssay. EVTadhesionassaywasperformed
aspreviouslydescribed[19],withsomemodiﬁcation.Brieﬂy,
96-well plate was coated with 10µg/mL of C1q (Quidel,
Medical Systems, Genoa, Italy), MBL (kindly provided by
Prof. Peter Garred, Department of Clinical Immunology,
Rigshospitalet, University of Copenhagen, Copenhagen,
Denmark), or BSA (Sigma-Aldrich) in bicarbonate buﬀer
at 4◦C overnight and blocked with 1% BSA for 1 hour
at room temperature. Cells were ﬂuorescently tagged with
the lipophilic dye DiI (Molecular Probes, Invitrogen), resus-
pended in RPMI with 0.1% BSA, and then added to protein-
precoated wells. Labelled EVT cells previously incubated
with sera (1:50) or MBL (2µg/mL) were added to C1q-
coated wells for 45min at 37◦Ci na na i r / C O 2 incubator. The
numberofadherentcellswerecountedwithInﬁnite200(ABS
544nm, EM 590nm) (TECAN Italia S.r.l.) with reference to
a calibration curves established with increasing number of
labeled EVT cells.
2.6. EVT/DEC Adhesion Assay. The assay to evaluate adhe-
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To evaluate the eﬀect of sera or MBL on the adherence of
trophoblast to DECs, DECs grown to conﬂuence on 96-
microwell plates (Costar, Milan, Italy) were cocultured for
45min at 37◦Ci na na i r / C O 2 incubator with an EVT cell
suspension (105 cells/100µL) labelled with a ﬂuorescent dye
(Fast DiI, Molecular Probes, Invitrogen) previously incu-
bated with sera (1:50) or MBL (2µg/mL). The nonadherent
EVT cells were removed by washing with Dulbecco-PBS
containing Ca2+ and Mg2+ (0.7mM). The number of adher-
ent cells were counted with Inﬁnite200 (ABS 544nm, EM
590nm) (TECAN Italia S.r.l., Milano, Italy) with reference
to a calibration curves established with increasing number of
labeled EVT cells.
2.7. Transendothelial Migration Assay. DECs (2 × 104)w e r e
seeded onto 20µg/mL ﬁbronectin-coated polycarbonate
insert of a 24-well FloroBlock Transwell system (6.5mm
diameter, 8-µm pores; BD Falcon) and used 5 days after
plating [3]. EVT cell suspension (105 cells/100µL) labelled
with Fast DiI was added to the upper compartment of the
transwell in the presence of sera (1:50) or MBL (2µg/mL).
EVT cells were allowed to migrate for 24h in human
endothelial serum-free medium supplemented with basic
FGF, recombinant EGF (Gibco Invitrogen). Cells present in
the lower chamber or adherent to the lower surface of the
transwell insert were counted with Inﬁnite200 (ABS 544nm,
EM 590nm) (TECAN Italia S.r.l.) with multiple reads of
samewellandthenumberofmigratedcellswereexpressedas
percentage with reference to a calibration curves established
with increasing number of labelled EVTs plated in the lower
chamber.
2.8. MBL-Binding Assay. To evaluate the binding of MBL
to EVT, 105 freshly isolated EVT cells were seeded onto
20µg/mL ﬁbronectin-coated 96-well plate. The cells were
incubated with 0.1µg/mL puriﬁed recombinant MBL, kindly
provided by Professor Peter Garred, for 2h at room temper-
ature. The binding of the protein to the cells was analyzed
using a monoclonal mouse antihuman MBL antibody (clone
HYB131-01, Bioporto/Antibodyshop) 5µg/mL, followed
by AP-conjugated secondary antibodies (Sigma-Aldrich)
1:10000. The enzymatic reaction was developed with PNPP
(p-nitrophenyl phosphate) (Sigma-Aldrich; 1mg/mL) as
substrate and read kinetically at 405nm using a Titertek
Multiskan ELISA reader (Flow Labs, Milano, Italy).
2.9. Statistical Analysis. Results are expressed as mean ± SD
or as box plot graphs, in which the line in the middle of the
box represents the median where the lower and the upper
edges of the box are the 1st and 3rd quartile, respectively.
Statistical signiﬁcance was determined using Student’s t test
to compare two groups of data. Values of P = 0.05 or less
were considered to be statistically signiﬁcant.
3. Results andDiscussion
3.1. Sera Obtained from PE Patients Aﬀect Trophoblast-
Endothelial Cell Interaction. We have previously demon-
strated that trophoblast cells are able to adhere and migrate
through endothelial cells [20]. A representative pattern of
EVT cells and DECs used in the present investigation is
shown in Figure 1. The eﬀect of sera collected from PE
and normal pregnant women at the same gestational age
is presented in Figure 2(a). The results clearly show a
signiﬁcantly lower adhesion of EVT to DECs in the presence
of pathological sera. The data were conﬁrmed in at least
three experiments using diﬀerent preparation of trophoblast
and endothelial cells. These results extend our previous
observations obtained with sera from patients suﬀering from
recurrent spontaneous abortion (RSA) [20]. These data
suggest that endovascular invasion of trophoblast cells may
be controlled by serum factors in several diseases associated
with pregnancy failure.
To further conﬁrm the contribution of sera obtained
from PE patients to the process of vascular remodelling, we
nextexaminedtheabilityoftheseseratoinﬂuencethemigra-
tion of EVT through DECs. To this end, FastDiI-labelled
EVT cells were allowed to migrate through to the monolayer
of DECs grown to conﬂuence on the insert of a transwell
system in the presence of decidual conditioned medium as
a source of chemotactic factors. Under these condition, the
numberofmigratingEVTcellswasapproximately70%(data
not shown). The migration rate increased to approximately
95% following the addition of sera obtained from normal
pregnant women. Conversely, the sera from PE patients
elicited a strong inhibitory eﬀect and cell migration dropped
to 35% (Figure 2(b)).
Since C1q synthesized by DECs during pregnancy acts
as a physical link between endovascular trophoblast and
DECs favouring the process of vascular remodelling [4],
we decided to investigate the eﬀect of serum from PE
patients and control pregnant women. The results presented
in Figure 2(c) show that the sera obtained from PE patients
signiﬁcantly reduce the adhesion of EVT cells to C1q.
3.2.MBLPresentinPESeraIsResponsiblefortheFailureofthe
Interaction of EVT to DECs. MBL is one of the complement
components that undergoes changes in pre-eclampsia. Than
et al. [13] have published data indicating that patients had
higher levels of plasma MBL compared to normal pregnant
women. We, therefore, wondered whether MBL may be one
of the factors responsible for the serum eﬀect on EVT cell
interaction with endothelial cells.
We initially evaluated the MBL concentration of sera
from PE patients and normal pregnant women used in the
inhibition experiments. The data shown in Figure 3 clear-
ly indicate that PE patients had a signiﬁcantly higher level
of serum MBL than control women, conﬁrming the observa-
tionbyThanetal.[13].TheincreaseinMBLinnormalpreg-
nancy with respect to the level found in nonpregnant wom-
en [14] and the further increase in MBL concentration in
patients with pre-eclampsia, which is considered an inﬂam-
matory condition [21], is in line with the fact that MBL acts
as an acute phase protein [22].
To investigate the eﬀect of MBL in the interaction
between EVT and DECs, EVT were incubated with 2µg/mL
recombinant MBL protein for 15min at 37◦Cp r i o rt ob e4 Clinical and Developmental Immunology
EVT
(a)
DEC
(b)
Figure 1: Immunoﬂuorescence analysis of cells isolated from ﬁrst trimester placenta. Puriﬁed EVTs were stained with mAb antihuman
cytokeratin 7 (a) and DECs (b) with monoclonal anti-VE-cadherin. Images were acquired with Leica DM3000 microscope. Original
magniﬁcation 100x.
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Figure 2: Eﬀect of serum from pre-eclamptic and normal pregnant women in EVT/DEC interaction. Analysis of the eﬀect of sera obtained
fromPEornormalwomenontheadhesionofEVTstoDECs(a),toC1q(c)andontransendothelialmigrationthroughDECs(b).EVTswere
preincubatedwithPEorcontrolsera(1:50).Theresultsareexpressedaspercentofadhesioninreferencetoastandardcurve.Foreachgroup,
the line in the middle of the box represents the median. The lower and the upper edges of the box are the 1st and 3rd quartile, respectively.
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Figure 3: Analysis of serum levels of MBL in pre-eclamptic and control women. The level of oligomerized MBL in sera was measured using
an MBL oligomer ELISA kit. The results are expressed as box plot graphs, in which the line in the middle of the box represents the median;
the lower and the upper edges of the box are the 1st and 3rd quartile, respectively.Clinical and Developmental Immunology 5
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Figure 4: Analysis of MBL eﬀect in the interaction between EVTs to DECs. To investigate the eﬀect of MBL in the interaction between EVTs
and DECs we performed adhesion (a) and migration assays through DECs, (b) in the presence of 2µg/mL of MBL. The graph in (c) conﬁrm
the ability of EVT to adhere to C1q, while MBL was not able to promote adhesion of EVT as compared to BSA used as negative control. The
ability of MBL to inhibit the adhesion process was also evaluated on the binding of EVT to C1q (C1q + MBL).
∗∗P<0.01;
∗∗∗P<0.001;
§P<0.00001.
tested in the adhesion and migration assays performed as
described above. As shown in Figure 4, both adhesion to and
migration of EVT through DECs were signiﬁcant lower in
the presence of MBL. The role of MBL was evaluated also
in EVT-C1q interaction. The data represented in Figure 4(c)
conﬁrmed the ability of EVT to adhere to C1q. MBL failed to
promote adhesion of EVT, compared to BSA used as negative
control but was able to substantially inhibit the adhesion of
EVT to C1q.
The binding site for MBL on EVT is still unknown. We
have collected evidence indicating that MBL binds strongly
to EVT (data not shown) and probably covers the binding
site for C1q. The gC1q/p33 receptor for the globular head of
C1q previously shown to be expressed on the surface of EVT
[4] is unlikely to be involved in MBL-mediated inhibition
of EVT-C1q interaction, since it is not an MBL receptor
[23]. The only putative receptors for MBL are calreticulin
and complement receptor-1 that bind to the tail domains of
C1q and function also as receptors for MBL [23, 24]. These
receptors, however, are present on ECs and interact with
both MBL and C1q which compete with each other for their
binding to the surface of ECs as shown by Oroszl` an et al.
in cross-inhibition experiments [25] .S i n c eD E C sa l r e a d y
express C1q on their surface, we postulate that MBL is
probablyunabletointeractwithECmembrane,thoughthese
data need to be conﬁrmed.
4. Conclusion
In this study, we have shown that sera obtained from PE
patients strongly inhibit the interaction between EVT and
DECs, thereby controlling endovascular invasion of tro-
phoblast cells, a fundamental process for the progression of
pregnancy.MBL,oneofthecomplementcomponentsshown
to be present at increased levels in PE patient sera, is respon-
sible for the inhibition of EVT adhesion to and migration
through DECs. Our data also show that MBL interferes with
the interaction of EVT with C1q expressed on DECs acting
as a molecular bridge between endovascular trophoblast and
DECs. The inhibitory eﬀect of MBL on EVT adhesion to
DECs is apparently unrelated to the ability of this comple-
ment component to activate the lectin pathway based on the6 Clinical and Developmental Immunology
observationthatthelevelsofMBL-MASP2complexes,which
represent activation products of this pathway, are essentially
similar in PE and control groups, indicating that the lectin
pathway activation plays only a minor role in complement
activation during pre-eclampsia [12]. On the basis of our re-
sults,wesuggestthatMBL,whichis presentatincreasedlevel
in PE patients, may be one of the factors interfering with the
endovascular invasion of trophoblast cells. Overall these data
further indicate that proteins belonging to the C system may
play alternative roles promoting physiological processes and
inducing tissue damage.
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